Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atanu Chakraborty

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
The EMBO Journal|April 30, 2013
Arginine methylation of the c-Jun coactivator RACO-1 is required for c-Jun/AP-1 activationClare C Davies, Atanu Chakraborty, Markus E Diefenbacher, et al.
Chemmedchem|September 18, 2018
Injectable Hydrogel of Vitamin BAditi Panja, Sujoy Das, Atanu Chakraborty, et al.
Journal of Tissue Engineering|March 18, 2020
Targeting with nanoparticles for the therapeutic treatment of brain diseasesGuang-Zhen Jin, Atanu Chakraborty, Jung-Hwan Lee, et al.
Lung India : Official Organ of Indian Chest Society|April 30, 2014
Recurrent subcutaneous emphysema in a treated pulmonary tuberculosis patient: Is there any association?Tony Ete, Sumantro Mondal, Debanjali Sinha, et al.
Nature Cell Biology|September 21, 2010
Identification of a co-activator that links growth factor signalling to c-Jun/AP-1 activationClare C Davies, Atanu Chakraborty, Filippo Cipriani, et al.
Cancer Research|February 27, 2015
Usp28 counteracts Fbw7 in intestinal homeostasis and cancerMarkus E Diefenbacher, Atanu Chakraborty, Sophia M Blake, et al.
Scientific Reports|February 18, 2022
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibitionTereza Vaclova, Atanu Chakraborty, James Sherwood, et al.
JCI Insight|July 8, 2021
JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancerE Josue Ruiz, Linxiang Lan, Markus Elmar Diefenbacher, et al.
The Journal of Experimental Medicine|January 16, 2019
LUBAC determines chemotherapy resistance in squamous cell lung cancerE Josue Ruiz, Markus E Diefenbacher, Jessica K Nelson, et al.
Molecular Cancer Therapeutics|August 5, 2022
AZD4625 is a Potent and Selective Inhibitor of KRASG12CAtanu Chakraborty, Lyndsey Hanson, David Robinson, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The EMBO Journal|April 30, 2013
Arginine methylation of the c-Jun coactivator RACO-1 is required for c-Jun/AP-1 activationClare C Davies, Atanu Chakraborty, Markus E Diefenbacher, et al.
Chemmedchem|September 18, 2018
Injectable Hydrogel of Vitamin BAditi Panja, Sujoy Das, Atanu Chakraborty, et al.
Journal of Tissue Engineering|March 18, 2020
Targeting with nanoparticles for the therapeutic treatment of brain diseasesGuang-Zhen Jin, Atanu Chakraborty, Jung-Hwan Lee, et al.
Lung India : Official Organ of Indian Chest Society|April 30, 2014
Recurrent subcutaneous emphysema in a treated pulmonary tuberculosis patient: Is there any association?Tony Ete, Sumantro Mondal, Debanjali Sinha, et al.
Nature Cell Biology|September 21, 2010
Identification of a co-activator that links growth factor signalling to c-Jun/AP-1 activationClare C Davies, Atanu Chakraborty, Filippo Cipriani, et al.
Cancer Research|February 27, 2015
Usp28 counteracts Fbw7 in intestinal homeostasis and cancerMarkus E Diefenbacher, Atanu Chakraborty, Sophia M Blake, et al.
Scientific Reports|February 18, 2022
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibitionTereza Vaclova, Atanu Chakraborty, James Sherwood, et al.
JCI Insight|July 8, 2021
JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancerE Josue Ruiz, Linxiang Lan, Markus Elmar Diefenbacher, et al.
The Journal of Experimental Medicine|January 16, 2019
LUBAC determines chemotherapy resistance in squamous cell lung cancerE Josue Ruiz, Markus E Diefenbacher, Jessica K Nelson, et al.
Molecular Cancer Therapeutics|August 5, 2022
AZD4625 is a Potent and Selective Inhibitor of KRASG12CAtanu Chakraborty, Lyndsey Hanson, David Robinson, et al.
Pageof 4